Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment

Advanced NanoTherapies, Inc. (ANT) has successfully closed an oversubscribed Series B financing round, raising over $31 million. The funding was co-led by an undisclosed strategic investor and S3 Ventures, with participation from the T45 Fund and both new and existing investors. This capital infusion, announced on June 2, 2026, will facilitate the advancement of ANT's innovative dual-drug nanoparticle-coated balloon platform designed for vascular treatment, specifically targeting U.S. Investigational Device Exemption (IDE) approval and clinical advancements.

ANT is at the forefront of redefining vascular intervention through its proprietary technology, SirPlux Duo. This dual-drug delivery system utilizes a unique nanoparticle platform to enhance the uptake of two established antiproliferation agents, sirolimus and paclitaxel, directly within the vessel wall. The aim is to improve therapeutic outcomes and provide a more predictable and sustained vascular response compared to traditional drug-coated balloons (DCBs), which typically utilize a single drug in a crystalline format. The company’s approach is particularly relevant as the market continues to grapple with the limitations of existing DCB technologies.

The current funding will enable ANT to scale its manufacturing capabilities to meet FDA IDE requirements and support its clinical trials, which are crucial for the commercialization of its technology. The company is focused on advancing two coronary indications: in-stent restenosis and small-vessel de novo lesions, while also pursuing a pivotal clinical trial agreement with the FDA for below-the-knee (BTK) applications. These efforts are underpinned by promising early clinical data, including a first-in-human study that demonstrated no new treatment failures over two years.

The strategic investment from S3 Ventures and other participants underscores the growing interest in innovative healthcare solutions that address significant clinical challenges, such as restenosis after percutaneous coronary intervention (PCI). ANT’s differentiated approach to drug delivery aims to mitigate the issues associated with cell proliferation at treatment sites, potentially offering a more effective solution for patients suffering from coronary and peripheral artery disease.

Looking ahead, the successful completion of this financing round positions ANT to make significant strides in the vascular intervention market. As the company advances its clinical programs and regulatory submissions, it may pave the way for a new category of drug-coated therapies that could improve patient outcomes. The broader implications of this funding extend to the healthcare sector, where advancements in medical technology continue to drive innovation and investment, particularly in areas that promise to enhance treatment efficacy and patient care.